Fibromyalgia is a disorder of central pain processing characterised by widespread musculoskeletal pain, fatigue, and sleep disturbance, often accompanied by cognitive difficulties ('fibro fog'). No primary tissue damage is evident; instead, dysregulation of pain-signal amplification in the spinal cord and brain—low serotonin, elevated substance P, sensitised pain receptors—perpetuates the syndrome. The condition predominantly affects women and is often triggered by trauma, infection, or stress. Cell therapy exploration in fibromyalgia is nascent; placental MSCs and their secreted exosomes are being investigated for immunomodulatory properties (shifting immune response away from pro-inflammatory cytokine production) and for potential neuromodulation through delivery of anti-inflammatory molecules to the central nervous system. The hypothesis is that systemic cellular or exosome infusion might dampen the amplified pain state and restore normal sleep and mood regulation.
Only 1 completed trial and 0 actively recruiting trials are registered specifically for fibromyalgia cell therapy, reflecting the early, exploratory stage of this application. That single published study involved placental MSC infusion in a small cohort (n≈20–30) and reported modest improvements in pain scores (average 20–30% reduction on visual analogue pain scale) and some improvement in fatigue severity. Biochemical markers of inflammation (IL-6, TNF-α) showed trending reductions. No control arm was present, and long-term follow-up was not reported.
Clinical applications of cell therapy for fibromyalgia are highly experimental and available in only a handful of private centres. Costs, where quoted, typically range from €4,000 to €7,000 for intravenous MSC infusion, though supportive testing (blood panels assessing cytokine profiles, baseline pain and fatigue questionnaires) may add €500–1,000. Insurance is not applicable because no standard treatment pathway exists; patients seeking this therapy are self-funding exploratory care.
Cell therapy for Fibromyalgia & Chronic Fatigue is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Fibromyalgia & Chronic Fatigue programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Fibromyalgia & Chronic Fatigue overview · Fibromyalgia & Chronic Fatigue cost →
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача